id,nct_id,outcome_id,result_group_id,ctgov_group_code,classification,category,title,description,units,param_type,param_value,param_value_num,dispersion_type,dispersion_value,dispersion_value_num,dispersion_lower_limit,dispersion_upper_limit,explanation_of_na
267526515,NCT00837577,35019995,62027101,OG000,NA,NA,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12,"Change from baseline measurement, where the baseline measurement was obtained at randomization (Week 0) before receiving study medication. This study used Japan Diabetes Society (JDS)-certified HbA1c values, the standard at the time when the study was conducted (HbA1c [National Glycohemoglobin Standardization Program; NGSP] = HbA1c (JDS-HbA1c [%]) + 0.4%).",Percentage of glycosylated hemoglobin,Least Squares Mean,-0.76,-0.76,95% Confidence Interval,0.42,0.42,-0.88,-0.63,NA
267526516,NCT00837577,35019995,62027102,OG001,NA,NA,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12,"Change from baseline measurement, where the baseline measurement was obtained at randomization (Week 0) before receiving study medication. This study used Japan Diabetes Society (JDS)-certified HbA1c values, the standard at the time when the study was conducted (HbA1c [National Glycohemoglobin Standardization Program; NGSP] = HbA1c (JDS-HbA1c [%]) + 0.4%).",Percentage of glycosylated hemoglobin,Least Squares Mean,0.16,0.16,95% Confidence Interval,0.64,0.64,0.02,0.3,NA
267526517,NCT00837577,35019996,62027101,OG000,NA,NA,Change From Baseline in 2-hour Postprandial Glucose at Week 12,"Change from baseline measurement, where the baseline measurement was obtained at randomization (Week 0) before receiving study medication.",mg/dL,Least Squares Mean,-55.3,-55.3,95% Confidence Interval,37.9,37.9,-64.2,-46.3,NA
267526518,NCT00837577,35019996,62027102,OG001,NA,NA,Change From Baseline in 2-hour Postprandial Glucose at Week 12,"Change from baseline measurement, where the baseline measurement was obtained at randomization (Week 0) before receiving study medication.",mg/dL,Least Squares Mean,-4,-4,95% Confidence Interval,38.7,38.7,-13.5,5.5,NA
267526519,NCT00837577,35019997,62027101,OG000,NA,NA,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12,"Change from baseline measurement, where the baseline measurement was obtained at randomization (Week 0) before receiving study medication.",mg/dL,Least Squares Mean,-22.6,-22.6,95% Confidence Interval,27.1,27.1,-28.5,-16.8,NA
267526520,NCT00837577,35019997,62027102,OG001,NA,NA,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12,"Change from baseline measurement, where the baseline measurement was obtained at randomization (Week 0) before receiving study medication.",mg/dL,Least Squares Mean,-0.1,-0.1,95% Confidence Interval,22.2,22.2,-6.4,6.2,NA
267561267,NCT00885352,35024259,62032569,OG000,NA,NA,Change From Baseline in Hemoglobin A1c (A1C) at Week 26,Change from baseline reflects the Week 26 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.,Percent of glycosylated hemoglobin,Least Squares Mean,-1.15,-1.15,95% Confidence Interval,0.93,0.93,-1.29,-1.01,NA
267561268,NCT00885352,35024259,62032570,OG001,NA,NA,Change From Baseline in Hemoglobin A1c (A1C) at Week 26,Change from baseline reflects the Week 26 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.,Percent of glycosylated hemoglobin,Least Squares Mean,-0.4,-0.4,95% Confidence Interval,1,1,-0.55,-0.26,NA
267561269,NCT00885352,35024260,62032569,OG000,NA,NA,Change From Baseline in 2-Hour Post-Meal Glucose (PMG) at Week 26,Change from baseline reflects the Week 26 value minus the baseline value.,mg/dL,Least Squares Mean,-54.4,-54.4,95% Confidence Interval,64.4,64.4,-63.3,-45.4,NA
267561270,NCT00885352,35024260,62032570,OG001,NA,NA,Change From Baseline in 2-Hour Post-Meal Glucose (PMG) at Week 26,Change from baseline reflects the Week 26 value minus the baseline value.,mg/dL,Least Squares Mean,-14.7,-14.7,95% Confidence Interval,59.6,59.6,-23.8,-5.6,NA
267561271,NCT00885352,35024261,62032569,OG000,NA,NA,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26,Change from baseline reflects the Week 26 value minus the baseline value.,mg/dL,Least Squares Mean,-20.3,-20.3,95% Confidence Interval,49.5,49.5,-27,-13.6,NA
267561272,NCT00885352,35024261,62032570,OG001,NA,NA,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26,Change from baseline reflects the Week 26 value minus the baseline value.,mg/dL,Least Squares Mean,-2.8,-2.8,95% Confidence Interval,41.6,41.6,-9.5,3.9,NA
267562038,NCT01076075,35024392,62032842,OG000,NA,NA,Change From Baseline in Hemoglobin A1C (%) at Week 24,Change from baseline reflects the Week 24 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.,Percentage of glycosylated hemoglobin,Least Squares Mean,-0.84,-0.84,95% Confidence Interval,0.82,0.82,-0.97,-0.71,NA
267562039,NCT01076075,35024392,62032843,OG001,NA,NA,Change From Baseline in Hemoglobin A1C (%) at Week 24,Change from baseline reflects the Week 24 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.,Percentage of glycosylated hemoglobin,Least Squares Mean,-0.16,-0.16,95% Confidence Interval,0.84,0.84,-0.28,-0.03,NA
267562040,NCT01076075,35024393,62032844,OG000,NA,NA,Change From Baseline in 2-hour Post-Meal Glucose at Week 24,Change from baseline reflects the Week 24 value minus the baseline value. Two-hour post-meal glucose was measured following a standard meal.,mg/dL,Least Squares Mean,-36.8,-36.8,95% Confidence Interval,60.8,60.8,-45.2,-28.4,NA
267562041,NCT01076075,35024393,62032843,OG001,NA,NA,Change From Baseline in 2-hour Post-Meal Glucose at Week 24,Change from baseline reflects the Week 24 value minus the baseline value. Two-hour post-meal glucose was measured following a standard meal.,mg/dL,Least Squares Mean,-3.3,-3.3,95% Confidence Interval,67.8,67.8,-11.7,5,NA
267562042,NCT01076075,35024394,62032844,OG000,NA,NA,Change From Baseline in Fasting Plasma Glucose at Week 24,Change from baseline reflects the Week 24 value minus the baseline value.,mg/dL,Least Squares Mean,-13.2,-13.2,95% Confidence Interval,NA,NA,-18.8,-7.7,NA
267562043,NCT01076075,35024394,62032843,OG001,NA,NA,Change From Baseline in Fasting Plasma Glucose at Week 24,Change from baseline reflects the Week 24 value minus the baseline value.,mg/dL,Least Squares Mean,5.3,5.3,95% Confidence Interval,NA,NA,-0.2,10.9,NA
267562044,NCT01076075,35024395,62032845,OG000,NA,NA,Number of Participants With One or More Adverse Events (AEs) - Week 0 to Week 54,NA,participants,Number,120,120,NA,NA,NA,NA,NA,NA
267562045,NCT01076075,35024395,62032846,OG001,NA,NA,Number of Participants With One or More Adverse Events (AEs) - Week 0 to Week 54,NA,participants,Number,122,122,NA,NA,NA,NA,NA,NA
267562046,NCT01076075,35024396,62032845,OG000,NA,NA,Number of Participants Discontinuing Study Drug Due to An Adverse Event,NA,participants,Number,3,3,NA,NA,NA,NA,NA,NA
267562047,NCT01076075,35024396,62032846,OG001,NA,NA,Number of Participants Discontinuing Study Drug Due to An Adverse Event,NA,participants,Number,9,9,NA,NA,NA,NA,NA,NA
269849218,NCT00984867,35301728,62392651,OG000,NA,NA,Adjusted Mean Change in HbA1c Levels,To compare the change from baseline in HbA1c after 24 weeks treatment (LOCF) between dapagliflozin and placebo in patients with type 2 diabetes who are inadequately controlled on sitagliptin alone or on sitagliptin plus metformin.,Percent,Least Squares Mean,0.04,0.04,95% Confidence Interval,0.0509,0.0509,-0.06,0.14,NA
269849219,NCT00984867,35301728,62392652,OG001,NA,NA,Adjusted Mean Change in HbA1c Levels,To compare the change from baseline in HbA1c after 24 weeks treatment (LOCF) between dapagliflozin and placebo in patients with type 2 diabetes who are inadequately controlled on sitagliptin alone or on sitagliptin plus metformin.,Percent,Least Squares Mean,-0.45,-0.45,95% Confidence Interval,0.0509,0.0509,-0.55,-0.35,NA
269849220,NCT00984867,35301729,62392653,OG000,NA,NA,Adjusted Mean Change in Body Weight,To compare the change in total body weight achieved with dapagliflozin versus placebo from baseline to week 24.,kg,Least Squares Mean,-0.26,-0.26,95% Confidence Interval,0.1741,0.1741,-0.6,0.09,NA
269849221,NCT00984867,35301729,62392654,OG001,NA,NA,Adjusted Mean Change in Body Weight,To compare the change in total body weight achieved with dapagliflozin versus placebo from baseline to week 24.,kg,Least Squares Mean,-2.14,-2.14,95% Confidence Interval,0.1745,0.1745,-2.48,-1.8,NA
269849222,NCT00984867,35301730,62392653,OG000,NA,NA,Adjusted Mean Change in HbA1c in Participants With Baseline HbA1c ≥8%,To compare the change in HbA1c in participants with baseline HbA1c ≥8% achieved with dapagliflozin versus placebo from baseline to week 24.,Percent,Least Squares Mean,0.03,0.03,95% Confidence Interval,0.0775,0.0775,-0.12,0.18,NA
269849223,NCT00984867,35301730,62392654,OG001,NA,NA,Adjusted Mean Change in HbA1c in Participants With Baseline HbA1c ≥8%,To compare the change in HbA1c in participants with baseline HbA1c ≥8% achieved with dapagliflozin versus placebo from baseline to week 24.,Percent,Least Squares Mean,-0.8,-0.8,95% Confidence Interval,0.0797,0.0797,-0.96,-0.65,NA
269849224,NCT00984867,35301731,62392653,OG000,NA,NA,Adjusted Mean Change in Fasting Plasma Glucose (FPG),To compare the change in FPG achieved with dapagliflozin versus placebo from baseline to week 24.,mg/dL,Least Squares Mean,3.81,3.81,95% Confidence Interval,2.3474,2.3474,-0.8,8.42,NA
269849225,NCT00984867,35301731,62392654,OG001,NA,NA,Adjusted Mean Change in Fasting Plasma Glucose (FPG),To compare the change in FPG achieved with dapagliflozin versus placebo from baseline to week 24.,mg/dL,Least Squares Mean,-24.11,-24.11,95% Confidence Interval,2.3474,2.3474,-28.73,-19.5,NA
269849226,NCT00984867,35301732,62392653,OG000,NA,NA,Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) in Participants With Baseline SBP>=130 mmHg,To compare the change in seated systolic blood pressure (SBP) in participants with baseline seated SBP >=130 achieved with dapagliflozin versus placebo from baseline to week 8.,mmHg,Least Squares Mean,-5.12,-5.12,95% Confidence Interval,1.0211,1.0211,-7.14,-3.11,NA
269849227,NCT00984867,35301732,62392654,OG001,NA,NA,Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) in Participants With Baseline SBP>=130 mmHg,To compare the change in seated systolic blood pressure (SBP) in participants with baseline seated SBP >=130 achieved with dapagliflozin versus placebo from baseline to week 8.,mmHg,Least Squares Mean,-5.98,-5.98,95% Confidence Interval,1.0638,1.0638,-8.08,-3.89,NA
269849228,NCT00984867,35301733,62392653,OG000,NA,NA,Adjusted Mean Change in 2-hour Post Liquid Meal Glucose Rise,To compare the change in 2-hour post liquid meal glucose rise achieved with dapagliflozin versus placebo from baseline to week 24.,mg/dL,Least Squares Mean,-6.84,-6.84,95% Confidence Interval,2.5098,2.5098,-11.77,-1.9,NA
269849229,NCT00984867,35301733,62392654,OG001,NA,NA,Adjusted Mean Change in 2-hour Post Liquid Meal Glucose Rise,To compare the change in 2-hour post liquid meal glucose rise achieved with dapagliflozin versus placebo from baseline to week 24.,mg/dL,Least Squares Mean,-21.65,-21.65,95% Confidence Interval,2.4604,2.4604,-26.49,-16.81,NA
269849230,NCT00984867,35301734,62392653,OG000,NA,NA,Proportion of Participants Achieving a Therapeutic Glycemic Response Defined as a Reduction in HbA1c of ≥0.7% Compared to Baseline,"To compare the proportion of participants achieving a therapeutic glycaemic response, defined as a reduction in HbA1c of ≥0.7% compared to baseline, with dapagliflozin versus placebo at week 24. Least Squares Mean represents the percent of participants adjusted for HbA1c baseline value.",Percentage of participants,Least Squares Mean,16.6,16.6,95% Confidence Interval,2.491,2.491,11.7,21.4,NA
269849231,NCT00984867,35301734,62392654,OG001,NA,NA,Proportion of Participants Achieving a Therapeutic Glycemic Response Defined as a Reduction in HbA1c of ≥0.7% Compared to Baseline,"To compare the proportion of participants achieving a therapeutic glycaemic response, defined as a reduction in HbA1c of ≥0.7% compared to baseline, with dapagliflozin versus placebo at week 24. Least Squares Mean represents the percent of participants adjusted for HbA1c baseline value.",Percentage of participants,Least Squares Mean,35.3,35.3,95% Confidence Interval,3.083,3.083,29.3,41.2,NA
270572370,NCT01703208,35424488,62593485,OG000,NA,NA,"Number of Participants With MACE-plus (Confirmed Cardiovascular [CV]-Related Death, Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, or Hospitalization Due to Unstable Angina)","Participants with confirmed MACE-plus events (confirmed cardiovascular, CV-related death, nonfatal myocardial infarction [MI], nonfatal stroke, or hospitalization due to unstable angina). In the MK-3102-018 study, MACE plus events had a data cut-off date of April 15, 2015.",Participants,Number,66,66,NA,NA,NA,-1.14,-0.9,NA
270572371,NCT01703208,35424488,62593486,OG001,NA,NA,"Number of Participants With MACE-plus (Confirmed Cardiovascular [CV]-Related Death, Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, or Hospitalization Due to Unstable Angina)","Participants with confirmed MACE-plus events (confirmed cardiovascular, CV-related death, nonfatal myocardial infarction [MI], nonfatal stroke, or hospitalization due to unstable angina). In the MK-3102-018 study, MACE plus events had a data cut-off date of April 15, 2015.",Participants,Number,70,70,NA,NA,NA,-1.2,-0.96,NA
270572372,NCT01703208,35424489,62593485,OG000,NA,NA,"Number of Participants With an Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke)","Participants with an Event of MACE (confirmed cardiovascular, CV-related death, fatal and nonfatal myocardial infarction [MI], and fatal and nonfatal stroke).",Participants,Number,114,114,NA,NA,NA,-1.14,-0.9,NA
270572373,NCT01703208,35424489,62593486,OG001,NA,NA,"Number of Participants With an Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke)","Participants with an Event of MACE (confirmed cardiovascular, CV-related death, fatal and nonfatal myocardial infarction [MI], and fatal and nonfatal stroke).",Participants,Number,114,114,NA,NA,NA,-1.2,-0.96,NA
270572374,NCT01703208,35424490,62593485,OG000,NA,NA,"Number of Participants With an Event Per 100 Person-Years for First Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke)","Participants with an event of MACE (confirmed cardiovascular, CV-related death, fatal and nonfatal myocardial infarction [MI], and fatal and nonfatal stroke). Person-years were calculated as the sum of all participants' follow-up time to first event.",Participants/100 Person-years,Number,2.96,2.96,NA,NA,NA,-1.14,-0.9,NA
270572375,NCT01703208,35424490,62593486,OG001,NA,NA,"Number of Participants With an Event Per 100 Person-Years for First Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke)","Participants with an event of MACE (confirmed cardiovascular, CV-related death, fatal and nonfatal myocardial infarction [MI], and fatal and nonfatal stroke). Person-years were calculated as the sum of all participants' follow-up time to first event.",Participants/100 Person-years,Number,2.97,2.97,NA,NA,NA,-1.2,-0.96,NA
270572376,NCT01703208,35424491,62593485,OG000,NA,NA,Change From Baseline in Hemoglobin A1C (A1C) at Week 18,A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 18 A1C minus the Week 0 A1C.,Percent,Least Squares Mean,-0.58,-0.58,95% Confidence Interval,0.82,0.82,-0.62,-0.55,NA
270572377,NCT01703208,35424491,62593486,OG001,NA,NA,Change From Baseline in Hemoglobin A1C (A1C) at Week 18,A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 18 A1C minus the Week 0 A1C.,Percent,Least Squares Mean,-0.16,-0.16,95% Confidence Interval,0.88,0.88,-0.19,-0.12,NA
270572378,NCT01703208,35424492,62593485,OG000,NA,NA,Change From Baseline in A1C at Week 18 in a Sub-Study of Participants Taking Insulin (With or Without Metformin),A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 18 A1C minus the Week 0 A1C.,Percentage,Least Squares Mean,-0.5,-0.5,95% Confidence Interval,NA,NA,-0.57,-0.42,NA
270572379,NCT01703208,35424492,62593486,OG001,NA,NA,Change From Baseline in A1C at Week 18 in a Sub-Study of Participants Taking Insulin (With or Without Metformin),A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 18 A1C minus the Week 0 A1C.,Percentage,Least Squares Mean,-0.11,-0.11,95% Confidence Interval,NA,NA,-0.19,-0.03,NA
270572380,NCT01703208,35424493,62593485,OG000,NA,NA,Percentage of Participants Who Experienced at Least One Adverse Event in a Sub-study of Participants Taking Insulin Excluding Data After Background Antihyperglycemic Agent (AHA) Change,"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.",Percentage of participants,Number,48.8,48.8,NA,NA,NA,NA,NA,NA
270572381,NCT01703208,35424493,62593486,OG001,NA,NA,Percentage of Participants Who Experienced at Least One Adverse Event in a Sub-study of Participants Taking Insulin Excluding Data After Background Antihyperglycemic Agent (AHA) Change,"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.",Percentage of participants,Number,49.9,49.9,NA,NA,NA,NA,NA,NA
270572382,NCT01703208,35424494,62593485,OG000,NA,NA,Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event in a Sub-Study of Participants Taking Insulin Excluding Data After Background AHA Change,"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.",Percentage of participants,Number,1.1,1.1,NA,NA,NA,-3.13,-2.25,NA
270572383,NCT01703208,35424494,62593486,OG001,NA,NA,Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event in a Sub-Study of Participants Taking Insulin Excluding Data After Background AHA Change,"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.",Percentage of participants,Number,0.8,0.8,NA,NA,NA,-4.18,-3.29,NA
270572384,NCT01703208,35424495,62593485,OG000,NA,NA,Number of Participants With an Event of CV-Related Death,Participants with adjudicated and confirmed AEs of cardiovascular-related death.,Participants,Number,37,37,NA,NA,NA,-40.04,-31.42,NA
270572385,NCT01703208,35424495,62593486,OG001,NA,NA,Number of Participants With an Event of CV-Related Death,Participants with adjudicated and confirmed AEs of cardiovascular-related death.,Participants,Number,35,35,NA,NA,NA,-41.21,-32.62,NA
270572386,NCT01703208,35424496,62593485,OG000,NA,NA,Number of Participants With an Event Per 100 Person-Years of CV-Related Death,Participants with adjudicated and confirmed AEs of cardiovascular-related death. Person-years were calculated as the sum of all participants' follow-up time to event.,Participants/100 person-years,Number,0.94,0.94,NA,NA,NA,-40.04,-31.42,NA
270572387,NCT01703208,35424496,62593486,OG001,NA,NA,Number of Participants With an Event Per 100 Person-Years of CV-Related Death,Participants with adjudicated and confirmed AEs of cardiovascular-related death. Person-years were calculated as the sum of all participants' follow-up time to event.,Participants/100 person-years,Number,0.89,0.89,NA,NA,NA,-41.21,-32.62,NA
270572388,NCT01703208,35424497,62593485,OG000,NA,NA,Number of Participants With an Event of First MI (Fatal and Non-fatal),Participants with adjudicated and confirmed AEs of fatal and non-fatal MI.,Participants,Number,52,52,NA,NA,NA,-40.04,-31.42,NA
270572389,NCT01703208,35424497,62593486,OG001,NA,NA,Number of Participants With an Event of First MI (Fatal and Non-fatal),Participants with adjudicated and confirmed AEs of fatal and non-fatal MI.,Participants,Number,60,60,NA,NA,NA,-41.21,-32.62,NA
270572390,NCT01703208,35424498,62593485,OG000,NA,NA,Number of Participants With an Event Per 100 Person-Years of First MI (Fatal and Non-fatal),Participants with adjudicated and confirmed AEs of fatal and non-fatal MI. Person-years were calculated as the sum of all participants' follow-up time to first event.,Participants/100 person-years,Number,1.34,1.34,NA,NA,NA,-40.04,-31.42,NA
270572391,NCT01703208,35424498,62593486,OG001,NA,NA,Number of Participants With an Event Per 100 Person-Years of First MI (Fatal and Non-fatal),Participants with adjudicated and confirmed AEs of fatal and non-fatal MI. Person-years were calculated as the sum of all participants' follow-up time to first event.,Participants/100 person-years,Number,1.55,1.55,NA,NA,NA,-41.21,-32.62,NA
270572392,NCT01703208,35424499,62593485,OG000,NA,NA,Number of Participants With an Event of Stroke (Fatal and Non-fatal),Participants with adjudicated and confirmed AEs fatal and non-fatal stroke.,Participants,Number,32,32,NA,NA,NA,-40.04,-31.42,NA
270572393,NCT01703208,35424499,62593486,OG001,NA,NA,Number of Participants With an Event of Stroke (Fatal and Non-fatal),Participants with adjudicated and confirmed AEs fatal and non-fatal stroke.,Participants,Number,34,34,NA,NA,NA,-41.21,-32.62,NA
270572394,NCT01703208,35424500,62593485,OG000,NA,NA,Number of Participants With an Event Per 100 Person-Years of First Stroke (Fatal and Non-fatal),Participants with adjudicated and confirmed AEs fatal and non-fatal stroke. Person-years were calculated as the sum of all participants' follow-up time to event.,Participants/100 person-years,Number,0.82,0.82,NA,NA,NA,-40.04,-31.42,NA
270572395,NCT01703208,35424500,62593486,OG001,NA,NA,Number of Participants With an Event Per 100 Person-Years of First Stroke (Fatal and Non-fatal),Participants with adjudicated and confirmed AEs fatal and non-fatal stroke. Person-years were calculated as the sum of all participants' follow-up time to event.,Participants/100 person-years,Number,0.88,0.88,NA,NA,NA,-41.21,-32.62,NA
270572396,NCT01703208,35424501,62593485,OG000,NA,NA,Number of Participants With an Event of All-Cause Death,All-cause death was death from any cause.,Participants,Number,64,64,NA,NA,NA,NA,NA,NA
270572397,NCT01703208,35424501,62593486,OG001,NA,NA,Number of Participants With an Event of All-Cause Death,All-cause death was death from any cause.,Participants,Number,50,50,NA,NA,NA,NA,NA,NA
270572398,NCT01703208,35424502,62593485,OG000,NA,NA,Number of Participants With an Event Per 100 Person-Years of the Event of All-Cause Death,All-cause death was death for any cause. Person-years were calculated as the sum of all participants' follow-up time to event.,Participants/100 Person-years,Number,1.63,1.63,NA,NA,NA,NA,NA,NA
270572399,NCT01703208,35424502,62593486,OG001,NA,NA,Number of Participants With an Event Per 100 Person-Years of the Event of All-Cause Death,All-cause death was death for any cause. Person-years were calculated as the sum of all participants' follow-up time to event.,Participants/100 Person-years,Number,1.28,1.28,NA,NA,NA,NA,NA,NA
270572400,NCT01703208,35424503,62593485,OG000,NA,NA,Change From Baseline in A1C at Week 142,A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 142 A1C minus the Week 0 A1C.,Percent,Least Squares Mean,-0.36,-0.36,95% Confidence Interval,0.06,0.06,-0.47,-0.25,NA
270572401,NCT01703208,35424503,62593486,OG001,NA,NA,Change From Baseline in A1C at Week 142,A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 142 A1C minus the Week 0 A1C.,Percent,Least Squares Mean,-0.06,-0.06,95% Confidence Interval,1.12,1.12,-0.17,0.05,NA
270572402,NCT01703208,35424507,62593485,OG000,NA,NA,Percentage of Participants Who Experienced at Least One Adverse Event,"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.",Percentage of participants,Number,78.3,78.3,NA,NA,NA,NA,NA,NA
270572403,NCT01703208,35424507,62593486,OG001,NA,NA,Percentage of Participants Who Experienced at Least One Adverse Event,"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.",Percentage of participants,Number,76.8,76.8,NA,NA,NA,NA,NA,NA
270572404,NCT01703208,35424508,62593485,OG000,NA,NA,Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event,"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.",Percentage of participants,Number,4.1,4.1,NA,NA,NA,NA,NA,NA
270572405,NCT01703208,35424508,62593486,OG001,NA,NA,Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event,"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.",Percentage of participants,Number,3.6,3.6,NA,NA,NA,NA,NA,NA
270572406,NCT01703208,35424509,62593485,OG000,NA,NA,Change From Baseline in FPG at Week 18 in a Sub-Study of Participants Taking Insulin,This change from baseline reflects the Week 18 FPG minus the Week 0 FPG.,mg/dL,Least Squares Mean,-6.8,-6.8,95% Confidence Interval,NA,NA,-12.1,-1.5,NA
270572407,NCT01703208,35424509,62593486,OG001,NA,NA,Change From Baseline in FPG at Week 18 in a Sub-Study of Participants Taking Insulin,This change from baseline reflects the Week 18 FPG minus the Week 0 FPG.,mg/dL,Least Squares Mean,-3.6,-3.6,95% Confidence Interval,NA,NA,-9.1,1.8,NA
270572408,NCT01703208,35424510,62593485,OG000,NA,NA,Percentage of Participants Achieving a Target A1C <7.0 % (53 mmol/Mol) at Week 18 in a Sub-Study of Participants Taking Insulin,A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Analysis was performed with multiple data imputation.,Percentage of participants,Number,22,22,95% Confidence Interval,NA,NA,18.5,26.1,NA
270572409,NCT01703208,35424510,62593486,OG001,NA,NA,Percentage of Participants Achieving a Target A1C <7.0 % (53 mmol/Mol) at Week 18 in a Sub-Study of Participants Taking Insulin,A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Analysis was performed with multiple data imputation.,Percentage of participants,Number,10.2,10.2,95% Confidence Interval,NA,NA,7.5,13.6,NA
270572410,NCT01703208,35424511,62593485,OG000,NA,NA,Number of Participants With an Event of First Hospitalization for Heart Failure (Exploratory),Participants with adjudicated and confirmed events of first hospitalization for heart failure.,Participants,Number,20,20,NA,NA,NA,NA,NA,NA
270572411,NCT01703208,35424511,62593486,OG001,NA,NA,Number of Participants With an Event of First Hospitalization for Heart Failure (Exploratory),Participants with adjudicated and confirmed events of first hospitalization for heart failure.,Participants,Number,33,33,NA,NA,NA,NA,NA,NA
270572412,NCT01703208,35424512,62593485,OG000,NA,NA,Number of Participants With an Event Per 100 Person-years of the Event of the First Hospitalization for Heart Failure (Exploratory),Participants with adjudicated and confirmed events of first hospitalization for heart failure. Person-years were calculated as the sum of all participants' follow-up time to event.,Participants/100 Person-years,Number,0.51,0.51,NA,NA,NA,NA,NA,NA
270572413,NCT01703208,35424512,62593486,OG001,NA,NA,Number of Participants With an Event Per 100 Person-years of the Event of the First Hospitalization for Heart Failure (Exploratory),Participants with adjudicated and confirmed events of first hospitalization for heart failure. Person-years were calculated as the sum of all participants' follow-up time to event.,Participants/100 Person-years,Number,0.85,0.85,NA,NA,NA,NA,NA,NA
270589298,NCT01462266,35426640,62596580,OG000,NA,NA,Change From Baseline in Daily Insulin Dose at Week 24,"Change in daily insulin dose following 24 weeks of therapy (i.e., daily insulin dose at Week 24 minus daily insulin dose at baseline)",International Units (IU),Least Squares Mean,19,19,95% Confidence Interval,19.6,19.6,16.5,21.6,NA
270589299,NCT01462266,35426640,62596581,OG001,NA,NA,Change From Baseline in Daily Insulin Dose at Week 24,"Change in daily insulin dose following 24 weeks of therapy (i.e., daily insulin dose at Week 24 minus daily insulin dose at baseline)",International Units (IU),Least Squares Mean,23.8,23.8,95% Confidence Interval,24,24,21.3,26.3,NA
270589300,NCT01462266,35426641,62596580,OG000,NA,NA,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,"A1C is measured as the percentage of glycosylated hemoglobin. Change in A1C following 24 weeks of therapy (i.e., A1C at Week 24 minus A1C at baseline)",Percent of total hemoglobin,Least Squares Mean,-1.31,-1.31,95% Confidence Interval,0.98,0.98,-1.43,-1.2,NA
270589301,NCT01462266,35426641,62596581,OG001,NA,NA,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,"A1C is measured as the percentage of glycosylated hemoglobin. Change in A1C following 24 weeks of therapy (i.e., A1C at Week 24 minus A1C at baseline)",Percent of total hemoglobin,Least Squares Mean,-0.87,-0.87,95% Confidence Interval,1.1,1.1,-0.98,-0.75,NA
270589302,NCT01462266,35426642,62596580,OG000,NA,NA,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,"Change in FPG (before breakfast) following 24 weeks of therapy (i.e., FPG at Week 24 minus FPG at baseline)",mg/dL,Least Squares Mean,-55.5,-55.5,95% Confidence Interval,52,52,-61.1,-49.9,NA
270589303,NCT01462266,35426642,62596581,OG001,NA,NA,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,"Change in FPG (before breakfast) following 24 weeks of therapy (i.e., FPG at Week 24 minus FPG at baseline)",mg/dL,Least Squares Mean,-44.8,-44.8,95% Confidence Interval,62.4,62.4,-50.4,-39.2,NA
270589304,NCT01462266,35426643,62596580,OG000,NA,NA,Percent of Participants Achieving Fasting Glucose Target at Any Time During the Study,The fasting glucose target was defined as 3 consecutive days with a fingerstick glucose of 72 to 100 mg/dL (4.0 - 5.6 mmol/L).,Percentage of participants,Number,77.4,77.4,95% Confidence Interval,NA,NA,72.6,82.2,NA
270589305,NCT01462266,35426643,62596581,OG001,NA,NA,Percent of Participants Achieving Fasting Glucose Target at Any Time During the Study,The fasting glucose target was defined as 3 consecutive days with a fingerstick glucose of 72 to 100 mg/dL (4.0 - 5.6 mmol/L).,Percentage of participants,Number,74.1,74.1,95% Confidence Interval,NA,NA,69,79.2,NA
270589306,NCT01462266,35426644,62596580,OG000,NA,NA,Time to Achieve the Fasting Glucose Target,Fasting glucose target 3 consecutive days with a fingerstick glucose of 72 to 100 mg/dL (4.0 - 5.6 mmol/L). This analysis was the Kaplan-Meier estimated 50th percentile of time (days) to first attainment of target.,Days to first attainment of target,Median,78,78,95% Confidence Interval,NA,NA,64,85,NA
270589307,NCT01462266,35426644,62596581,OG001,NA,NA,Time to Achieve the Fasting Glucose Target,Fasting glucose target 3 consecutive days with a fingerstick glucose of 72 to 100 mg/dL (4.0 - 5.6 mmol/L). This analysis was the Kaplan-Meier estimated 50th percentile of time (days) to first attainment of target.,Days to first attainment of target,Median,90,90,95% Confidence Interval,NA,NA,80,107,NA
267204686,NCT01296412,34982837,61978266,OG000,NA,NA,Change From Baseline in Hemoglobin A1c (A1C),"A1C is measured as percent. Thus, this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent.",percent,Least Squares Mean,-1.32,-1.32,95% Confidence Interval,1.06,1.06,-1.42,-1.23,NA
267204687,NCT01296412,34982837,61978267,OG001,NA,NA,Change From Baseline in Hemoglobin A1c (A1C),"A1C is measured as percent. Thus, this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent.",percent,Least Squares Mean,-1.42,-1.42,95% Confidence Interval,1.04,1.04,-1.51,-1.32,NA
267204688,NCT01296412,34982838,61978266,OG000,NA,NA,Change From Baseline in Fasting Plasma Glucose (FPG),Change from baseline at Week 26 is defined as Week 26 minus Week 0.,mg/dL,Least Squares Mean,-33.7,-33.7,95% Confidence Interval,46.2,46.2,-37.5,-29.9,NA
267204689,NCT01296412,34982838,61978267,OG001,NA,NA,Change From Baseline in Fasting Plasma Glucose (FPG),Change from baseline at Week 26 is defined as Week 26 minus Week 0.,mg/dL,Least Squares Mean,-39.6,-39.6,95% Confidence Interval,40.3,40.3,-43.6,-35.7,NA
267204690,NCT01296412,34982839,61978266,OG000,NA,NA,Percentage of Participants Reaching A1C Goal of <7.0%,NA,percentage of participants,Number,62.8,62.8,NA,NA,NA,NA,NA,NA
267204691,NCT01296412,34982839,61978267,OG001,NA,NA,Percentage of Participants Reaching A1C Goal of <7.0%,NA,percentage of participants,Number,72.3,72.3,NA,NA,NA,NA,NA,NA
267204692,NCT01296412,34982840,61978266,OG000,NA,NA,Percentage of Participants Reaching A1C Goal of <6.5%,NA,percentage of participants,Number,33.8,33.8,NA,NA,NA,NA,NA,NA
267204693,NCT01296412,34982840,61978267,OG001,NA,NA,Percentage of Participants Reaching A1C Goal of <6.5%,NA,percentage of participants,Number,38.3,38.3,NA,NA,NA,NA,NA,NA
269192217,NCT02738879,35222088,62280275,OG000,NA,NA,Change From Baseline in A1C at Week 30,"A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 30 A1C minus the Week 0 A1C.",Percent A1C,Least Squares Mean,-1.88,-1.88,95% Confidence Interval,-1.98,-1.98,-1.98,-1.78,NA
269192218,NCT02738879,35222088,62280276,OG001,NA,NA,Change From Baseline in A1C at Week 30,"A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 30 A1C minus the Week 0 A1C.",Percent A1C,Least Squares Mean,-1.42,-1.42,95% Confidence Interval,-1.52,-1.52,-1.52,-1.32,NA
269192219,NCT02738879,35222089,62280275,OG000,NA,NA,Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L),"Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.",Events/Participant-Years,Number,1.55,1.55,95% Confidence Interval,1.22,1.22,1.22,1.96,NA
269192220,NCT02738879,35222089,62280276,OG001,NA,NA,Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L),"Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.",Events/Participant-Years,Number,2.12,2.12,95% Confidence Interval,1.7,1.7,1.7,2.66,NA
269192221,NCT02738879,35222090,62280275,OG000,NA,NA,Percentage of Participants Who Discontinued Study Drug Due to an AE,"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.",Percentage of participants,Number,1.3,1.3,NA,NA,NA,NA,NA,NA
269192222,NCT02738879,35222090,62280276,OG001,NA,NA,Percentage of Participants Who Discontinued Study Drug Due to an AE,"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.",Percentage of participants,Number,1.6,1.6,NA,NA,NA,NA,NA,NA
269192223,NCT02738879,35222091,62280275,OG000,NA,NA,Percentage of Participants With Events of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L),"Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The incidence (number of participants with ≥1 event divided by number of participants) of documented symptomatic hypoglycemia was determined.",Percentage of participants,Number,33.5,33.5,95% Confidence Interval,28.5,28.5,28.5,38.6,NA
269192224,NCT02738879,35222091,62280276,OG001,NA,NA,Percentage of Participants With Events of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L),"Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The incidence (number of participants with ≥1 event divided by number of participants) of documented symptomatic hypoglycemia was determined.",Percentage of participants,Number,37.7,37.7,95% Confidence Interval,32.7,32.7,32.7,42.6,NA
269192225,NCT02738879,35222092,62280275,OG000,NA,NA,Change From Baseline in Total Daily Insulin Dose (Units) at Week 30,"Change from baseline reflects the Week 30 total daily insulin dose minus the Week 0 total daily insulin dose. The Week 0 total daily insulin dose was 0, by definition, because insulin was not administered at baseline.",Insulin Units,Least Squares Mean,53.2,53.2,95% Confidence Interval,48.5,48.5,48.5,58,NA
269192226,NCT02738879,35222092,62280276,OG001,NA,NA,Change From Baseline in Total Daily Insulin Dose (Units) at Week 30,"Change from baseline reflects the Week 30 total daily insulin dose minus the Week 0 total daily insulin dose. The Week 0 total daily insulin dose was 0, by definition, because insulin was not administered at baseline.",Insulin Units,Least Squares Mean,61.3,61.3,95% Confidence Interval,56.5,56.5,56.5,66,NA
269192227,NCT02738879,35222093,62280275,OG000,NA,NA,Event Rate of Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L),"Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.",Events/Participant-Years,Number,5.05,5.05,95% Confidence Interval,4.34,4.34,4.34,5.88,NA
269192228,NCT02738879,35222093,62280276,OG001,NA,NA,Event Rate of Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L),"Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.",Events/Participant-Years,Number,6.21,6.21,95% Confidence Interval,5.33,5.33,5.33,7.24,NA
269192229,NCT02738879,35222094,62280275,OG000,NA,NA,Event Rate of Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L),"Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration <56 mg/dL (≤3.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.",Events/Participant-Years,Number,0.3,0.3,95% Confidence Interval,0.2,0.2,0.2,0.45,NA
269192230,NCT02738879,35222094,62280276,OG001,NA,NA,Event Rate of Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L),"Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration <56 mg/dL (≤3.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.",Events/Participant-Years,Number,0.36,0.36,95% Confidence Interval,0.25,0.25,0.25,0.53,NA
269192231,NCT02738879,35222095,62280275,OG000,NA,NA,Percentage of Participants With Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L),"Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration <56 mg/dL (≤3.1 mmol/L).",Percentage of participants,Number,12.4,12.4,95% Confidence Interval,8.9,8.9,8.9,15.8,NA
269192232,NCT02738879,35222095,62280276,OG001,NA,NA,Percentage of Participants With Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L),"Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration <56 mg/dL (≤3.1 mmol/L).",Percentage of participants,Number,13.6,13.6,95% Confidence Interval,10,10,10,17.2,NA
269192233,NCT02738879,35222096,62280275,OG000,NA,NA,Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol) at Week 30,A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.,Percentage of participants,Number,54.2,54.2,NA,NA,NA,NA,NA,NA
269192234,NCT02738879,35222096,62280276,OG001,NA,NA,Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol) at Week 30,A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.,Percentage of participants,Number,35.4,35.4,NA,NA,NA,NA,NA,NA
269192235,NCT02738879,35222097,62280275,OG000,NA,NA,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30,"Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at Week 0).",mg/dL,Least Squares Mean,-84.8,-84.8,95% Confidence Interval,-90,-90,-90,-79.6,NA
269192236,NCT02738879,35222097,62280276,OG001,NA,NA,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30,"Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at Week 0).",mg/dL,Least Squares Mean,-78.3,-78.3,95% Confidence Interval,-83.5,-83.5,-83.5,-73.1,NA
269192237,NCT02738879,35222098,62280275,OG000,NA,NA,Percentage of Participants Who Experienced One or More Adverse Events (AEs),"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.",Percentage of participants,Number,57.9,57.9,NA,NA,NA,NA,NA,NA
269192238,NCT02738879,35222098,62280276,OG001,NA,NA,Percentage of Participants Who Experienced One or More Adverse Events (AEs),"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.",Percentage of participants,Number,60,60,NA,NA,NA,NA,NA,NA
269192239,NCT02738879,35222099,62280275,OG000,NA,NA,Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L),"Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration <56 mg/dL (≤3.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.",Events/Participant-Years,Number,0.17,0.17,95% Confidence Interval,0.1,0.1,0.1,0.28,NA
269192240,NCT02738879,35222099,62280276,OG001,NA,NA,Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L),"Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration <56 mg/dL (≤3.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.",Events/Participant-Years,Number,0.22,0.22,95% Confidence Interval,0.14,0.14,0.14,0.36,NA
269192241,NCT02738879,35222100,62280275,OG000,NA,NA,Percentage of Participants With Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L),"Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L).",Percentage of participants,Number,66.8,66.8,95% Confidence Interval,61.9,61.9,61.9,71.7,NA
269192242,NCT02738879,35222100,62280276,OG001,NA,NA,Percentage of Participants With Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L),"Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L).",Percentage of participants,Number,68,68,95% Confidence Interval,63.2,63.2,63.2,72.9,NA
269192243,NCT02738879,35222101,62280275,OG000,NA,NA,Percentage of Participants With Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L),"Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration <56 mg/dL (≤3.1 mmol/L).",Percentage of participants,Number,7.6,7.6,95% Confidence Interval,4.9,4.9,4.9,10.3,NA
269192244,NCT02738879,35222101,62280276,OG001,NA,NA,Percentage of Participants With Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L),"Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration <56 mg/dL (≤3.1 mmol/L).",Percentage of participants,Number,8.3,8.3,95% Confidence Interval,5.4,5.4,5.4,11.2,NA
269192245,NCT02738879,35222102,62280275,OG000,NA,NA,Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol at Week 30 and No Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) up to Week 30,A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.,Percentage of participants,Number,15.3,15.3,NA,NA,NA,NA,NA,NA
269192246,NCT02738879,35222102,62280276,OG001,NA,NA,Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol at Week 30 and No Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) up to Week 30,A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.,Percentage of participants,Number,10,10,NA,NA,NA,NA,NA,NA
267878691,NCT00813995,35060900,62079686,OG000,NA,NA,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,"A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.",Percent,Least Squares Mean,-1.02,-1.02,95% Confidence Interval,0.99,0.99,-1.16,-0.87,NA
267878692,NCT00813995,35060900,62079687,OG001,NA,NA,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,"A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.",Percent,Least Squares Mean,-0.14,-0.14,95% Confidence Interval,1.22,1.22,-0.28,0.01,NA
267878693,NCT00813995,35060901,62079688,OG000,NA,NA,Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1000 mg/Day,"A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.",Percent,Least Squares Mean,-0.84,-0.84,95% Confidence Interval,1.09,1.09,-1.07,-0.62,NA
267878694,NCT00813995,35060901,62079689,OG001,NA,NA,Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1000 mg/Day,"A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.",Percent,Least Squares Mean,-0.01,-0.01,95% Confidence Interval,1.31,1.31,-0.23,0.2,NA
267878695,NCT00813995,35060902,62079690,OG000,NA,NA,Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1700 mg/Day,"A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.",Percent,Least Squares Mean,-1.14,-1.14,95% Confidence Interval,0.88,0.88,-1.35,-0.93,NA
267878696,NCT00813995,35060902,62079691,OG001,NA,NA,Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1700 mg/Day,"A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.",Percent,Least Squares Mean,-0.21,-0.21,95% Confidence Interval,1.12,1.12,-0.43,0.02,NA
267878697,NCT00813995,35060903,62079686,OG000,NA,NA,Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24,Change from baseline at Week 24 is defined as Week 24 minus Week 0.,mg/dL,Least Squares Mean,-43.4,-43.4,95% Confidence Interval,57.3,57.3,-51.5,-35.3,NA
267878698,NCT00813995,35060903,62079687,OG001,NA,NA,Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24,Change from baseline at Week 24 is defined as Week 24 minus Week 0.,mg/dL,Least Squares Mean,-10,-10,95% Confidence Interval,60,60,-18.4,-1.7,NA
267878699,NCT00813995,35060904,62079686,OG000,NA,NA,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,Change from baseline at Week 24 is defined as Week 24 minus Week 0.,mg/dL,Least Squares Mean,-20.3,-20.3,95% Confidence Interval,39.1,39.1,-26.2,-14.5,NA
267878700,NCT00813995,35060904,62079687,OG001,NA,NA,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,Change from baseline at Week 24 is defined as Week 24 minus Week 0.,mg/dL,Least Squares Mean,0.5,0.5,95% Confidence Interval,40.1,40.1,-5.3,6.4,NA
270018277,NCT01042977,35327964,62433742,OG000,NA,NA,Adjusted Mean Change in HbA1c Levels,"To compare the glycemic efficacy of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease, measured as the mean change in HbA1c from baseline to week 24.",Percent,Least Squares Mean,-0.33,-0.33,95% Confidence Interval,0.0434,0.0434,-0.42,-0.25,NA
270018278,NCT01042977,35327964,62433743,OG001,NA,NA,Adjusted Mean Change in HbA1c Levels,"To compare the glycemic efficacy of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease, measured as the mean change in HbA1c from baseline to week 24.",Percent,Least Squares Mean,0.07,0.07,95% Confidence Interval,NA,NA,-0.02,0.15,NA
270018279,NCT01042977,35327965,62433742,OG000,NA,NA,Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit,"To compare the clinical benefit of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease at week 24, measured as the proportion of responders for a 3-item endpoint of clinical benefit, defined as an absolute drop of 0.5% or more from baseline HbA1c, and a relative drop of 3% or more from baseline for total body weight, and an absolute drop of 3 mmHg or more from baseline in seated systolic blood pressure.",Percentage of participants,Number,10,10,95% Confidence Interval,0.7,0.7,7.3,12.8,NA
270018280,NCT01042977,35327965,62433743,OG001,NA,NA,Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit,"To compare the clinical benefit of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease at week 24, measured as the proportion of responders for a 3-item endpoint of clinical benefit, defined as an absolute drop of 0.5% or more from baseline HbA1c, and a relative drop of 3% or more from baseline for total body weight, and an absolute drop of 3 mmHg or more from baseline in seated systolic blood pressure.",Percentage of participants,Number,1.9,1.9,95% Confidence Interval,7.3,7.3,0.7,3.2,NA
270018281,NCT01042977,35327966,62433742,OG000,NA,NA,Adjusted Mean Percent Change in Body Weight,To compare the mean percent change in body weight from baseline to week 24 between dapagliflozin 10 mg versus placebo.,Percentage of Body Weight,Least Squares Mean,-2.53,-2.53,95% Confidence Interval,0.177,0.177,-2.87,-2.18,NA
270018282,NCT01042977,35327966,62433743,OG001,NA,NA,Adjusted Mean Percent Change in Body Weight,To compare the mean percent change in body weight from baseline to week 24 between dapagliflozin 10 mg versus placebo.,Percentage of Body Weight,Least Squares Mean,-0.61,-0.61,95% Confidence Interval,0.1736,0.1736,-0.96,-0.26,NA
270018283,NCT01042977,35327967,62433742,OG000,NA,NA,Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²,To compare the proportion of participants with BMI baseline ≥27 kg/m2 with a reduction from baseline of 5% or more in body weight with dapagliflozin 10 mg versus placebo from baseline to week 24. Least Squares Mean represents the percent of participants adjusted for baseline body weight and age stratum.,Percentage of participants,Least Squares Mean,18.4,18.4,95% Confidence Interval,1.051,1.051,14.8,22.1,NA
270018284,NCT01042977,35327967,62433743,OG001,NA,NA,Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²,To compare the proportion of participants with BMI baseline ≥27 kg/m2 with a reduction from baseline of 5% or more in body weight with dapagliflozin 10 mg versus placebo from baseline to week 24. Least Squares Mean represents the percent of participants adjusted for baseline body weight and age stratum.,Percentage of participants,Least Squares Mean,4.8,4.8,95% Confidence Interval,1.876,1.876,2.8,6.9,NA
270018285,NCT01042977,35327968,62433742,OG000,NA,NA,Adjusted Mean Change in Systolic Blood Pressure at Week 8 (LOCF),To compare the mean change in seated systolic blood pressure from baseline to week 8 between dapagliflozin 10 mg versus placebo.,mmHg,Least Squares Mean,-1.85,-1.85,95% Confidence Interval,0.7105,0.7105,-3.25,-0.45,NA
270018286,NCT01042977,35327968,62433743,OG001,NA,NA,Adjusted Mean Change in Systolic Blood Pressure at Week 8 (LOCF),To compare the mean change in seated systolic blood pressure from baseline to week 8 between dapagliflozin 10 mg versus placebo.,mmHg,Least Squares Mean,0.86,0.86,95% Confidence Interval,0.7135,0.7135,-0.53,2.26,NA
270018287,NCT01042977,35327969,62433742,OG000,NA,NA,Adjusted Mean Change in Seated Systolic Blood Pressure at Week 24 (LOCF),To compare the mean change in seated systolic blood pressure from baseline to week 24 between dapagliflozin 10 mg versus placebo.,mmHg,Least Squares Mean,-2.7,-2.7,95% Confidence Interval,0.7109,0.7109,-4.1,-1.3,NA
270018288,NCT01042977,35327969,62433743,OG001,NA,NA,Adjusted Mean Change in Seated Systolic Blood Pressure at Week 24 (LOCF),To compare the mean change in seated systolic blood pressure from baseline to week 24 between dapagliflozin 10 mg versus placebo.,mmHg,Least Squares Mean,0.32,0.32,95% Confidence Interval,0.714,0.714,-1.07,1.72,NA
270018289,NCT01042977,35327970,62433742,OG000,NA,NA,Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 8 (LOCF) in Participants With Baseline SBP>=130 mmHg,To compare the mean change in seated systolic blood pressure (SBP) in participants with baseline seated SBP ≥130 mmHg achieved with dapagliflozin versus placebo from baseline to week 8.,mmHg,Least Squares Mean,-5.33,-5.33,95% Confidence Interval,0.8612,0.8612,-7.02,-3.64,NA
270018290,NCT01042977,35327970,62433743,OG001,NA,NA,Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 8 (LOCF) in Participants With Baseline SBP>=130 mmHg,To compare the mean change in seated systolic blood pressure (SBP) in participants with baseline seated SBP ≥130 mmHg achieved with dapagliflozin versus placebo from baseline to week 8.,mmHg,Least Squares Mean,-1.89,-1.89,95% Confidence Interval,0.8612,0.8612,-3.58,-0.2,NA
267451426,NCT01189890,35011511,62015707,OG000,NA,NA,Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30,Participant whole blood samples were collected at baseline and Week 30 to determine the LS mean HbA1c change from baseline. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.,Percentage of HbA1c,Least Squares Mean,-0.32,-0.32,95% Confidence Interval,0.78,0.78,-0.51,-0.14,NA
267451427,NCT01189890,35011511,62015708,OG001,NA,NA,Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30,Participant whole blood samples were collected at baseline and Week 30 to determine the LS mean HbA1c change from baseline. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.,Percentage of HbA1c,Least Squares Mean,-0.51,-0.51,95% Confidence Interval,0.89,0.89,-0.69,-0.33,NA
267451428,NCT01189890,35011512,62015707,OG000,NA,NA,Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30,"Symptomatic hypoglycemia was defined as an episode with clinical symptoms attributed to hypoglycemia, without regard to glucose level. Participants were instructed to complete the Hypoglycemia Assessment Log (HAL) for any symptomatic episodes he or she believed represent hypoglycemia. If a fingerstick glucose was obtained before or shortly (i.e., within a few minutes) after treating, the value was recorded in the HAL. In addition, participants were instructed to record in the HAL any fingerstick glucose values ≤70 mg/dL (≤3.9 mmol/L) regardless of the presence of clinical symptoms.",Participants,Number,2,2,NA,NA,NA,NA,NA,NA
267451429,NCT01189890,35011512,62015708,OG001,NA,NA,Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30,"Symptomatic hypoglycemia was defined as an episode with clinical symptoms attributed to hypoglycemia, without regard to glucose level. Participants were instructed to complete the Hypoglycemia Assessment Log (HAL) for any symptomatic episodes he or she believed represent hypoglycemia. If a fingerstick glucose was obtained before or shortly (i.e., within a few minutes) after treating, the value was recorded in the HAL. In addition, participants were instructed to record in the HAL any fingerstick glucose values ≤70 mg/dL (≤3.9 mmol/L) regardless of the presence of clinical symptoms.",Participants,Number,11,11,NA,NA,NA,NA,NA,NA
267451430,NCT01189890,35011513,62015707,OG000,NA,NA,Number of Participants Experiencing An Adverse Event (AE),"An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the

study treatment, whether or not considered related to the use of the treatment administered.",Participants,Number,118,118,NA,NA,NA,NA,NA,NA
267451431,NCT01189890,35011513,62015708,OG001,NA,NA,Number of Participants Experiencing An Adverse Event (AE),"An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the

study treatment, whether or not considered related to the use of the treatment administered.",Participants,Number,115,115,NA,NA,NA,NA,NA,NA
267451432,NCT01189890,35011514,62015707,OG000,NA,NA,Number of Participants Discontinuing Study Treatment Due to An AE,"An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the

study treatment, whether or not considered related to the use of the treatment administered.",Participants,Number,3,3,NA,NA,NA,NA,NA,NA
267451433,NCT01189890,35011514,62015708,OG001,NA,NA,Number of Participants Discontinuing Study Treatment Due to An AE,"An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the

study treatment, whether or not considered related to the use of the treatment administered.",Participants,Number,4,4,NA,NA,NA,NA,NA,NA
267451434,NCT01189890,35011515,62015707,OG000,NA,NA,LS Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30,Plasma samples were collected from participants after an overnight fast at baseline and Week 30 to determine the mean change from baseline in participant FPG.,mg/dL,Least Squares Mean,-14.5,-14.5,95% Confidence Interval,39,39,-21.6,-7.4,NA
267451435,NCT01189890,35011515,62015708,OG001,NA,NA,LS Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30,Plasma samples were collected from participants after an overnight fast at baseline and Week 30 to determine the mean change from baseline in participant FPG.,mg/dL,Least Squares Mean,-21.2,-21.2,95% Confidence Interval,39.1,39.1,-28.3,-14,NA
267451436,NCT01189890,35011516,62015707,OG000,NA,NA,Percentage of Participants With HbA1c <7.0% at Week 30,Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c <7.0% at Week 30. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.,Percentage of Participants,Number,33.5,33.5,NA,NA,NA,NA,NA,NA
267451437,NCT01189890,35011516,62015708,OG001,NA,NA,Percentage of Participants With HbA1c <7.0% at Week 30,Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c <7.0% at Week 30. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.,Percentage of Participants,Number,46.6,46.6,NA,NA,NA,NA,NA,NA
267451438,NCT01189890,35011517,62015707,OG000,NA,NA,Percentage of Participants With HbA1c <6.5% at Week 30,Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c <6.5% at Week 30. Hemoglobin A1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.,Percentage of Participants,Number,9.1,9.1,NA,NA,NA,NA,NA,NA
267451439,NCT01189890,35011517,62015708,OG001,NA,NA,Percentage of Participants With HbA1c <6.5% at Week 30,Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c <6.5% at Week 30. Hemoglobin A1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.,Percentage of Participants,Number,20.9,20.9,NA,NA,NA,NA,NA,NA
267451440,NCT01189890,35011518,62015707,OG000,NA,NA,LS Mean Change From Baseline in Participant Body Weight at Week 30,"Participants were only permitted to wear a drape gown and undergarments (no street clothes, no shoes or socks) for this evaluation. Body weight was measured after voiding (to the nearest 0.1 kg) and measurements were collected until 2 consecutive measurements did not differ by more than 0.2 kg from each other. Body weight measurements were evaluated using a standardized, calibrated digital scale and was reported in kilograms (kg) at baseline and Week 30.",kg,Least Squares Mean,0.4,0.4,95% Confidence Interval,3.2,3.2,-0.2,1,NA
267451441,NCT01189890,35011518,62015708,OG001,NA,NA,LS Mean Change From Baseline in Participant Body Weight at Week 30,"Participants were only permitted to wear a drape gown and undergarments (no street clothes, no shoes or socks) for this evaluation. Body weight was measured after voiding (to the nearest 0.1 kg) and measurements were collected until 2 consecutive measurements did not differ by more than 0.2 kg from each other. Body weight measurements were evaluated using a standardized, calibrated digital scale and was reported in kilograms (kg) at baseline and Week 30.",kg,Least Squares Mean,1.1,1.1,95% Confidence Interval,2.8,2.8,0.5,1.7,NA
268925619,NCT02973477,35188927,62238646,OG000,value at 12 weeks minus value at 1st baseline,NA,Changes in Measure of Heart Rate Variability Using Dapagliflozin vs Active Comparator Glimepiride.,"Heart Rate Variability, as shown by the difference of the LF:HF ratio from baseline to 12 weeks per arm (two 12-week periods with a 2-week washout period. The frequency domain measures [ low-frequency (LF) power (0.04-0.15 Hz), high-frequency (HF) power (0.15-0.4 Hz), and LF:HF ratio] are obtained by spectral analysis of R-R interval from continuous electrocardiogram recordings to evaluate for sympathetic/parasympathetic (autonomic nervous function) balance.",LF:HF ratio,Mean,-0.18,-0.18,Standard Deviation,1.51,1.51,NA,NA,NA
268925620,NCT02973477,35188927,62238647,OG001,value at 12 weeks minus value at 1st baseline,NA,Changes in Measure of Heart Rate Variability Using Dapagliflozin vs Active Comparator Glimepiride.,"Heart Rate Variability, as shown by the difference of the LF:HF ratio from baseline to 12 weeks per arm (two 12-week periods with a 2-week washout period. The frequency domain measures [ low-frequency (LF) power (0.04-0.15 Hz), high-frequency (HF) power (0.15-0.4 Hz), and LF:HF ratio] are obtained by spectral analysis of R-R interval from continuous electrocardiogram recordings to evaluate for sympathetic/parasympathetic (autonomic nervous function) balance.",LF:HF ratio,Mean,-0.34,-0.34,Standard Deviation,1.54,1.54,NA,NA,NA
268925621,NCT02973477,35188927,62238646,OG000,value at 26 weeks minus value at 2nd baseline,NA,Changes in Measure of Heart Rate Variability Using Dapagliflozin vs Active Comparator Glimepiride.,"Heart Rate Variability, as shown by the difference of the LF:HF ratio from baseline to 12 weeks per arm (two 12-week periods with a 2-week washout period. The frequency domain measures [ low-frequency (LF) power (0.04-0.15 Hz), high-frequency (HF) power (0.15-0.4 Hz), and LF:HF ratio] are obtained by spectral analysis of R-R interval from continuous electrocardiogram recordings to evaluate for sympathetic/parasympathetic (autonomic nervous function) balance.",LF:HF ratio,Mean,0.26,0.26,Standard Deviation,1.85,1.85,NA,NA,NA
268925622,NCT02973477,35188927,62238647,OG001,value at 26 weeks minus value at 2nd baseline,NA,Changes in Measure of Heart Rate Variability Using Dapagliflozin vs Active Comparator Glimepiride.,"Heart Rate Variability, as shown by the difference of the LF:HF ratio from baseline to 12 weeks per arm (two 12-week periods with a 2-week washout period. The frequency domain measures [ low-frequency (LF) power (0.04-0.15 Hz), high-frequency (HF) power (0.15-0.4 Hz), and LF:HF ratio] are obtained by spectral analysis of R-R interval from continuous electrocardiogram recordings to evaluate for sympathetic/parasympathetic (autonomic nervous function) balance.",LF:HF ratio,Mean,0.26,0.26,Standard Deviation,1.92,1.92,NA,NA,NA
268925623,NCT02973477,35188928,62238648,OG000,SDNN before treatment,NA,Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride.,"Changes in measures of HRV as defined by: Time domain measures of HRV (continuous variables): (i) standard deviation of the normal RR interval (SDNN) (msec) and (ii) root mean square of the differences of successive RR intervals (rmsSD) (msec).

Time domain (SDNN and rmsSD) measures of the normal R-R intervals are derived from HRV studies using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.) under paced breathing, reflecting parasympathetic activity.

Time domain measures of the normal R-R intervals, basically reflecting parasympathetic activity, include: the difference between the longest and shortestR-R interval, standard deviation of 5-min average of normal R-R intervals (SDANN), root-mean square of the difference of successive R-R intervals (rMSSD).",msec,Mean,40.72,40.72,Standard Deviation,16.63,16.63,NA,NA,NA
268925624,NCT02973477,35188928,62238649,OG001,SDNN before treatment,NA,Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride.,"Changes in measures of HRV as defined by: Time domain measures of HRV (continuous variables): (i) standard deviation of the normal RR interval (SDNN) (msec) and (ii) root mean square of the differences of successive RR intervals (rmsSD) (msec).

Time domain (SDNN and rmsSD) measures of the normal R-R intervals are derived from HRV studies using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.) under paced breathing, reflecting parasympathetic activity.

Time domain measures of the normal R-R intervals, basically reflecting parasympathetic activity, include: the difference between the longest and shortestR-R interval, standard deviation of 5-min average of normal R-R intervals (SDANN), root-mean square of the difference of successive R-R intervals (rMSSD).",msec,Mean,39.75,39.75,Standard Deviation,16.15,16.15,NA,NA,NA
268925625,NCT02973477,35188928,62238648,OG000,SDNN after treatment,NA,Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride.,"Changes in measures of HRV as defined by: Time domain measures of HRV (continuous variables): (i) standard deviation of the normal RR interval (SDNN) (msec) and (ii) root mean square of the differences of successive RR intervals (rmsSD) (msec).

Time domain (SDNN and rmsSD) measures of the normal R-R intervals are derived from HRV studies using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.) under paced breathing, reflecting parasympathetic activity.

Time domain measures of the normal R-R intervals, basically reflecting parasympathetic activity, include: the difference between the longest and shortestR-R interval, standard deviation of 5-min average of normal R-R intervals (SDANN), root-mean square of the difference of successive R-R intervals (rMSSD).",msec,Mean,37.74,37.74,Standard Deviation,16.04,16.04,NA,NA,NA
268925626,NCT02973477,35188928,62238649,OG001,SDNN after treatment,NA,Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride.,"Changes in measures of HRV as defined by: Time domain measures of HRV (continuous variables): (i) standard deviation of the normal RR interval (SDNN) (msec) and (ii) root mean square of the differences of successive RR intervals (rmsSD) (msec).

Time domain (SDNN and rmsSD) measures of the normal R-R intervals are derived from HRV studies using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.) under paced breathing, reflecting parasympathetic activity.

Time domain measures of the normal R-R intervals, basically reflecting parasympathetic activity, include: the difference between the longest and shortestR-R interval, standard deviation of 5-min average of normal R-R intervals (SDANN), root-mean square of the difference of successive R-R intervals (rMSSD).",msec,Mean,36.46,36.46,Standard Deviation,17.68,17.68,NA,NA,NA
268925627,NCT02973477,35188928,62238648,OG000,rmsSD before treatment,NA,Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride.,"Changes in measures of HRV as defined by: Time domain measures of HRV (continuous variables): (i) standard deviation of the normal RR interval (SDNN) (msec) and (ii) root mean square of the differences of successive RR intervals (rmsSD) (msec).

Time domain (SDNN and rmsSD) measures of the normal R-R intervals are derived from HRV studies using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.) under paced breathing, reflecting parasympathetic activity.

Time domain measures of the normal R-R intervals, basically reflecting parasympathetic activity, include: the difference between the longest and shortestR-R interval, standard deviation of 5-min average of normal R-R intervals (SDANN), root-mean square of the difference of successive R-R intervals (rMSSD).",msec,Mean,26.91,26.91,Standard Deviation,17.81,17.81,NA,NA,NA
268925628,NCT02973477,35188928,62238649,OG001,rmsSD before treatment,NA,Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride.,"Changes in measures of HRV as defined by: Time domain measures of HRV (continuous variables): (i) standard deviation of the normal RR interval (SDNN) (msec) and (ii) root mean square of the differences of successive RR intervals (rmsSD) (msec).

Time domain (SDNN and rmsSD) measures of the normal R-R intervals are derived from HRV studies using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.) under paced breathing, reflecting parasympathetic activity.

Time domain measures of the normal R-R intervals, basically reflecting parasympathetic activity, include: the difference between the longest and shortestR-R interval, standard deviation of 5-min average of normal R-R intervals (SDANN), root-mean square of the difference of successive R-R intervals (rMSSD).",msec,Mean,25.14,25.14,Standard Deviation,13.06,13.06,NA,NA,NA
268925629,NCT02973477,35188928,62238648,OG000,rmsSD after treatment,NA,Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride.,"Changes in measures of HRV as defined by: Time domain measures of HRV (continuous variables): (i) standard deviation of the normal RR interval (SDNN) (msec) and (ii) root mean square of the differences of successive RR intervals (rmsSD) (msec).

Time domain (SDNN and rmsSD) measures of the normal R-R intervals are derived from HRV studies using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.) under paced breathing, reflecting parasympathetic activity.

Time domain measures of the normal R-R intervals, basically reflecting parasympathetic activity, include: the difference between the longest and shortestR-R interval, standard deviation of 5-min average of normal R-R intervals (SDANN), root-mean square of the difference of successive R-R intervals (rMSSD).",msec,Mean,24.3,24.3,Standard Deviation,16.44,16.44,NA,NA,NA
268925630,NCT02973477,35188928,62238649,OG001,rmsSD after treatment,NA,Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride.,"Changes in measures of HRV as defined by: Time domain measures of HRV (continuous variables): (i) standard deviation of the normal RR interval (SDNN) (msec) and (ii) root mean square of the differences of successive RR intervals (rmsSD) (msec).

Time domain (SDNN and rmsSD) measures of the normal R-R intervals are derived from HRV studies using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.) under paced breathing, reflecting parasympathetic activity.

Time domain measures of the normal R-R intervals, basically reflecting parasympathetic activity, include: the difference between the longest and shortestR-R interval, standard deviation of 5-min average of normal R-R intervals (SDANN), root-mean square of the difference of successive R-R intervals (rMSSD).",msec,Mean,24.63,24.63,Standard Deviation,17.38,17.38,NA,NA,NA
268925631,NCT02973477,35188929,62238650,OG000,E/I ratio before treatment,NA,Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs),"Changes in CARTs as defined by: i) expiration/inspiration (E/I) ratio, ii) Valsalva ratio and iii) 30:15 ratio. Cardiovascular autonomic reflex tests assess the cardiovascular autonomic function using provocative physiological maneuvers under paced breathing [R-R response to breathing (E:I ratio), to Valsalva maneuver (Valsalva ratio) and to postural changes (30:15 ratio)] at baseline and at the end of each study drug period using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.).",ratio,Mean,1.13,1.13,Standard Deviation,0.07,0.07,NA,NA,NA
268925632,NCT02973477,35188929,62238651,OG001,E/I ratio before treatment,NA,Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs),"Changes in CARTs as defined by: i) expiration/inspiration (E/I) ratio, ii) Valsalva ratio and iii) 30:15 ratio. Cardiovascular autonomic reflex tests assess the cardiovascular autonomic function using provocative physiological maneuvers under paced breathing [R-R response to breathing (E:I ratio), to Valsalva maneuver (Valsalva ratio) and to postural changes (30:15 ratio)] at baseline and at the end of each study drug period using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.).",ratio,Mean,1.14,1.14,Standard Deviation,0.08,0.08,NA,NA,NA
268925633,NCT02973477,35188929,62238650,OG000,EI ratio after treatment,NA,Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs),"Changes in CARTs as defined by: i) expiration/inspiration (E/I) ratio, ii) Valsalva ratio and iii) 30:15 ratio. Cardiovascular autonomic reflex tests assess the cardiovascular autonomic function using provocative physiological maneuvers under paced breathing [R-R response to breathing (E:I ratio), to Valsalva maneuver (Valsalva ratio) and to postural changes (30:15 ratio)] at baseline and at the end of each study drug period using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.).",ratio,Mean,1.14,1.14,Standard Deviation,0.11,0.11,NA,NA,NA
268925634,NCT02973477,35188929,62238651,OG001,EI ratio after treatment,NA,Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs),"Changes in CARTs as defined by: i) expiration/inspiration (E/I) ratio, ii) Valsalva ratio and iii) 30:15 ratio. Cardiovascular autonomic reflex tests assess the cardiovascular autonomic function using provocative physiological maneuvers under paced breathing [R-R response to breathing (E:I ratio), to Valsalva maneuver (Valsalva ratio) and to postural changes (30:15 ratio)] at baseline and at the end of each study drug period using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.).",ratio,Mean,1.14,1.14,Standard Deviation,0.13,0.13,NA,NA,NA
268925635,NCT02973477,35188929,62238650,OG000,Valsalva ratio before treatment,NA,Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs),"Changes in CARTs as defined by: i) expiration/inspiration (E/I) ratio, ii) Valsalva ratio and iii) 30:15 ratio. Cardiovascular autonomic reflex tests assess the cardiovascular autonomic function using provocative physiological maneuvers under paced breathing [R-R response to breathing (E:I ratio), to Valsalva maneuver (Valsalva ratio) and to postural changes (30:15 ratio)] at baseline and at the end of each study drug period using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.).",ratio,Mean,1.5,1.5,Standard Deviation,0.36,0.36,NA,NA,NA
268925636,NCT02973477,35188929,62238651,OG001,Valsalva ratio before treatment,NA,Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs),"Changes in CARTs as defined by: i) expiration/inspiration (E/I) ratio, ii) Valsalva ratio and iii) 30:15 ratio. Cardiovascular autonomic reflex tests assess the cardiovascular autonomic function using provocative physiological maneuvers under paced breathing [R-R response to breathing (E:I ratio), to Valsalva maneuver (Valsalva ratio) and to postural changes (30:15 ratio)] at baseline and at the end of each study drug period using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.).",ratio,Mean,1.44,1.44,Standard Deviation,0.29,0.29,NA,NA,NA
268925637,NCT02973477,35188929,62238650,OG000,Valsalva ratio after treatment,NA,Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs),"Changes in CARTs as defined by: i) expiration/inspiration (E/I) ratio, ii) Valsalva ratio and iii) 30:15 ratio. Cardiovascular autonomic reflex tests assess the cardiovascular autonomic function using provocative physiological maneuvers under paced breathing [R-R response to breathing (E:I ratio), to Valsalva maneuver (Valsalva ratio) and to postural changes (30:15 ratio)] at baseline and at the end of each study drug period using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.).",ratio,Mean,1.6,1.6,Standard Deviation,0.66,0.66,NA,NA,NA
268925638,NCT02973477,35188929,62238651,OG001,Valsalva ratio after treatment,NA,Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs),"Changes in CARTs as defined by: i) expiration/inspiration (E/I) ratio, ii) Valsalva ratio and iii) 30:15 ratio. Cardiovascular autonomic reflex tests assess the cardiovascular autonomic function using provocative physiological maneuvers under paced breathing [R-R response to breathing (E:I ratio), to Valsalva maneuver (Valsalva ratio) and to postural changes (30:15 ratio)] at baseline and at the end of each study drug period using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.).",ratio,Mean,1.58,1.58,Standard Deviation,0.85,0.85,NA,NA,NA
268925639,NCT02973477,35188929,62238650,OG000,30:15 ratio before treatment,NA,Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs),"Changes in CARTs as defined by: i) expiration/inspiration (E/I) ratio, ii) Valsalva ratio and iii) 30:15 ratio. Cardiovascular autonomic reflex tests assess the cardiovascular autonomic function using provocative physiological maneuvers under paced breathing [R-R response to breathing (E:I ratio), to Valsalva maneuver (Valsalva ratio) and to postural changes (30:15 ratio)] at baseline and at the end of each study drug period using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.).",ratio,Mean,1.17,1.17,Standard Deviation,0.15,0.15,NA,NA,NA
268925640,NCT02973477,35188929,62238651,OG001,30:15 ratio before treatment,NA,Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs),"Changes in CARTs as defined by: i) expiration/inspiration (E/I) ratio, ii) Valsalva ratio and iii) 30:15 ratio. Cardiovascular autonomic reflex tests assess the cardiovascular autonomic function using provocative physiological maneuvers under paced breathing [R-R response to breathing (E:I ratio), to Valsalva maneuver (Valsalva ratio) and to postural changes (30:15 ratio)] at baseline and at the end of each study drug period using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.).",ratio,Mean,1.14,1.14,Standard Deviation,0.09,0.09,NA,NA,NA
268925641,NCT02973477,35188929,62238650,OG000,30:15 ratio after treatment,NA,Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs),"Changes in CARTs as defined by: i) expiration/inspiration (E/I) ratio, ii) Valsalva ratio and iii) 30:15 ratio. Cardiovascular autonomic reflex tests assess the cardiovascular autonomic function using provocative physiological maneuvers under paced breathing [R-R response to breathing (E:I ratio), to Valsalva maneuver (Valsalva ratio) and to postural changes (30:15 ratio)] at baseline and at the end of each study drug period using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.).",ratio,Mean,1.14,1.14,Standard Deviation,0.11,0.11,NA,NA,NA
268925642,NCT02973477,35188929,62238651,OG001,30:15 ratio after treatment,NA,Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs),"Changes in CARTs as defined by: i) expiration/inspiration (E/I) ratio, ii) Valsalva ratio and iii) 30:15 ratio. Cardiovascular autonomic reflex tests assess the cardiovascular autonomic function using provocative physiological maneuvers under paced breathing [R-R response to breathing (E:I ratio), to Valsalva maneuver (Valsalva ratio) and to postural changes (30:15 ratio)] at baseline and at the end of each study drug period using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.).",ratio,Mean,1.14,1.14,Standard Deviation,0.1,0.1,NA,NA,NA
268925643,NCT02973477,35188930,62238650,OG000,BNP before treatment,NA,Change in B-type Natriuretic Peptide With Each Intervention as a Measure of Left Ventricular Function,Changes in B-type Natriuretic Peptide (BNP) with each intervention as a measure of left ventricular function.,pg/ml,Mean,12.72,12.72,Standard Deviation,9.76,9.76,NA,NA,NA
268925644,NCT02973477,35188930,62238652,OG001,BNP before treatment,NA,Change in B-type Natriuretic Peptide With Each Intervention as a Measure of Left Ventricular Function,Changes in B-type Natriuretic Peptide (BNP) with each intervention as a measure of left ventricular function.,pg/ml,Mean,16.93,16.93,Standard Deviation,13.69,13.69,NA,NA,NA
268925645,NCT02973477,35188930,62238650,OG000,BNP after treatment,NA,Change in B-type Natriuretic Peptide With Each Intervention as a Measure of Left Ventricular Function,Changes in B-type Natriuretic Peptide (BNP) with each intervention as a measure of left ventricular function.,pg/ml,Mean,14.76,14.76,Standard Deviation,13.41,13.41,NA,NA,NA
268925646,NCT02973477,35188930,62238652,OG001,BNP after treatment,NA,Change in B-type Natriuretic Peptide With Each Intervention as a Measure of Left Ventricular Function,Changes in B-type Natriuretic Peptide (BNP) with each intervention as a measure of left ventricular function.,pg/ml,Mean,15.49,15.49,Standard Deviation,11.58,11.58,NA,NA,NA
